Benzinga | Nov 12, 2020 04:05PM EST

Capricor Therapeutics Q3 EPS $(0.20) Beats $(0.37) Estimate, Sales $16.86K Miss $210.00K Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.37) by 45.95 percent. This is a 53.49 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $16.86 thousand which missed the analyst consensus estimate of $210.00 thousand by 91.97 percent. This is a 88.13 percent decrease over sales of $142.07 thousand the same period last year.